Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC – NEW ENGLAND JOURNAL OF MEDICINE

Cho, BC; Lu, S; Felip, E; Spira, AI; Girard, N; Lee, JS; Lee, SH; Ostapenko, Y; Danchaivijitr, P; Liu, BG; Alip, A; Korbenfeld, E; Dias, JM; Besse, B; Lee, KH; Xiong, HL; How, SH; Cheng, Y; Chang, GC; Yoshioka, H; Yang, JCH; Thomas, M; Nguyen, D; Ou, SHI; Mukhedkar, S; Prabhash, K; D’Arcangelo, M; Alatorre-Alexander, J; Limon, JCV; Alves, S; Stroyakovskiy, D; Peregudova, M; Sendur, MAN; Yazici, O; Califano, R; Calderon, VG; de Marinis, F; Passaro, A; Kim, SW; Gadgeel, SM; Xie, JH; Sun, T; Martinez, M; Ennis, M; Fennema, E; Daksh, M; Millington, D; Leconte, I; Iwasawa, R; Lorenzini, P; Baig, M; Shah, SJ; Bauml, JM; Shreeve, SM; Sethi, S; Knoblauch, RE; Hayashi, H – 2024 – 10.1056/NEJMoa2403614